IXHL Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$18.87median target· current $2.52 (+648.8%)1 analyst
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—Forward 3.78
EPS (TTM)$-1.660.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$31.6MMicro cap
Valuation
- Forward P/E
- 3.78
- PEG ratio
- —
- P/B
- 0.47
- P/S (TTM)
- 84.20
- EV/EBITDA
- -5.13
Profitability & growth
- ROE (TTM)
- -47.8%
- Operating margin
- 0.0%
- Revenue growth YoY
- -100.0%
- Dividend yield
- —
- Beta
- 2.82
Last earnings
Sep 25, 2026 · Estimate $0.13 · Reported $-0.14
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Incannex Healthcare Inc.
Company profileIncannex Healthcare Limited is engaged in the research, development and sale of medicinal cannabinoid products in Australia. The company is headquartered in Sydney, Australia.
Classification
- Sector
- Healthcare
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- RIALTO SOUTH TOWER LEVEL 23, MELBOURNE, VIC
- Fiscal year end
- June
- Latest quarter
- Jun 30, 2026
Market cap$31.6M
Shares outstanding$12.5M
52W high$14.91
52W low$2.49
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent